.jpeg)
Sotorasib (Lumakras): Indications, Dosing, Safety and the Next-Gen KRAS G12C Landscape
KRAS was long called“undruggable”until sotorasib changed the premise.By covalently locking the G12C-mutant protein in its inactive state,it turned a dead-end target into a treatable one.Accelerated FDA approval came in 2021 for NSCLC;in 2025,a panitumumab combination added metastatic colorectal cancer.By 2026,next-generation agents are resetting the bar—but sotorasib remains the molecule with the deepest real-world footprint.
Two indications,two clear lines
NSCLC:adults with KRAS G12C-mutant locally advanced or metastatic disease after at least one prior systemic therapy.
Colorectal cancer:KRAS G12C-mutant metastatic disease progressing after fluoropyrimidine,oxaliplatin and irinotecan,combined with panitumumab.
A confirmed G12C result—tissue or qualified plasma—is mandatory.
Dosing and daily use
960mg once daily by mouth,with or without food,at a consistent time.Tablet strength follows the prescribed pack;never self-adjust the count.
Missed dose>6 hours:skip,resume next day.
Vomiting after dosing:no replacement dose.
Swallow whole,or disperse in room-temperature still water within 2 hours if needed.
Avoid PPIs/H2 blockers;space antacids if unavoidable.
With panitumumab:take sotorasib before infusion;hold both if either is paused.
Efficacy:progress,with honest limits
CodeBreaK 200(pre-treated NSCLC):mPFS 5.6 vs 4.5 months,ORR 28.1%vs 13.2%;median OS 10.6 vs 11.3 months—no OS superiority.
CodeBreaK 300(colorectal):960mg+panitumumab mPFS 5.6 vs 2.0 months,~52%lower progression/death risk,ORR~26%–30%;OS not statistically significant.
2026 NEJM Krascendo 1:Divarasib vs sotorasib/adagrasib showed PFS 9.8 vs 5.7 months,OS 17.7 vs 12.0 months,ORR 58.4%vs 32.3%,with fewer grade 3–4 events.Sotorasib becomes the benchmark to beat.
Safety:liver and lungs are non-negotiable
Hepatotoxicity:monitor ALT/AST before treatment,every 3 weeks for the first 3 months,then monthly;interrupt,reduce or stop per label.
ILD/pneumonitis:new cough,dyspnea or fever—stop and evaluate;permanent discontinuation if confirmed.
Common:diarrhea,nausea,musculoskeletal pain,fatigue.
Drug interactions:review acid-reducing agents and CYP substrates/inducers.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
